Muutke küpsiste eelistusi

ICH Quality Guidelines: An Implementation Guide [Kõva köide]

Edited by , Edited by , Edited by
  • Formaat: Hardback, 736 pages, kõrgus x laius x paksus: 234x158x38 mm, kaal: 1225 g
  • Ilmumisaeg: 15-Dec-2017
  • Kirjastus: John Wiley & Sons Inc
  • ISBN-10: 1118971116
  • ISBN-13: 9781118971116
Teised raamatud teemal:
  • Formaat: Hardback, 736 pages, kõrgus x laius x paksus: 234x158x38 mm, kaal: 1225 g
  • Ilmumisaeg: 15-Dec-2017
  • Kirjastus: John Wiley & Sons Inc
  • ISBN-10: 1118971116
  • ISBN-13: 9781118971116
Teised raamatud teemal:
"Examining the implications and practical implementation of multi-disciplinary International Conference on Harmonization (ICH) topics, this book gives an integrated view of how the guidelines inform drug development strategic planning and decision-making. Addresses a consistent need for interpretation, training, and implementation examples of ICH guidelines via case studies. Offers a primary reference point for practitioners addressing the dual challenge of interpretation and practical implementation of ICH guidelines. Uses case studies to help readers understand and apply ICH guidelines. Provides valuable insights into guidelines development, with chapters by authors involved in generating or with experience implementing the guidelines. Includes coverage of stability testing, analytical method validation, impurities, biotechnology drugs and products, and good manufacturing practice (GMP)"--

Examining the implications and practical implementation of multi-disciplinary International Conference on Harmonization (ICH) topics, this book gives an integrated view of how the guidelines inform drug development strategic planning and decision-making.

•    Addresses a consistent need for interpretation, training, and implementation examples of ICH guidelines via case studies
•    Offers a primary reference point for practitioners addressing the dual challenge of interpretation and practical implementation of ICH guidelines
•    Uses case studies to help readers understand and apply ICH guidelines
•    Provides valuable insights into guidelines development, with chapters by authors involved in generating or with experience implementing the guidelines
•    Includes coverage of stability testing, analytical method validation, impurities, biotechnology drugs and products, and good manufacturing practice (GMP)
List of Contributors
ix
An Introduction to ICH Quality Guidelines: Opportunities and Challenges 1(2)
1 ICHQ1A(R2) Stability Testing of New Drug Substance and Product and ICHQ1C Stability Testing of New Dosage Forms
3(42)
Andy Rignall
2 Stability Testing: Photostability Testing of New Drug Substances and Products ICH Q1B
45(28)
David Clapham
3 ICH Q1D: Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products
73(16)
Raymond Peter Munden
4 ICH Q1E Evaluation for Stability Data
89(38)
Garry Scrivens
5 Q2(R1) Validation of Analytical Procedures: Text and Methodology
127(40)
Phillip Borman
David Elder
6 Impurities in New Drug Substances and New Drug Products: ICH Q3A/B: Key Guidelines in the General Impurity Management Process
167(32)
Andrew Teasdale
David Elder
James Harvey
Steven Spanhaak
7 ICH Q3C Impurities: Guideline for Residual Solvents
199(34)
John Connelly
8 ICH Q3D Elemental Impurities
233(48)
Andrew Teasdale
Sarah Thompson
9 ICH Q4: Pharmacopeial Harmonization and Evaluation and Recommendation of Pharmacopeial Texts for Use in the ICH Regions
281(30)
David Elder
10 ICH Q5A: Viral Safety of Biotechnology Products
311(26)
Daniel Galbraith
11 ICH Q5B Analysis of the Expression Construct in Cell Lines Used for Production of Recombinant DNA-Derived Protein Products
337(8)
Jianxin Ye
Zhong Liu
David Pollard
12 ICH Q5C Stability Testing of Biotechnological/Biological Products
345(30)
John G. Davies
Di Gao
Yoen Joo Kim
Richard Harris
Patricia W. Cash
Timothy L. Schofield
Roujian Zhang
Qiang Qin
13 Q5D Derivation and Characterization of Cell Substrates Used for Production of Biotechnological/Biological Products
375(20)
Mark Plavsic
14 Conduct of Risk Assessments: An Integral Part of Compliance with ICH Q5A and ICH Q5D
395(14)
Raymond W. Nims
15 ICH Q5E Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Processes: Summary and Analysis of ICH Q5E Guideline
409(24)
Ramani R. Raghavan
Robert McCombie
16 ICH Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances
433(34)
David Elder
17 ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products
467(20)
Scott R. Rudge
Raymond W. Nims
18 Process-Related Impurities in Biopharmaceuticals: A Deeper Dive into ICH Q6B
487(22)
Anil Raghani
Kim Li
Jeanine L. Bussiere
Joel P. Bercu
Jinshu Qiu
19 ICH Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients (APIs)
509(26)
Gordon Munro
20 Q8(R2): Pharmaceutical Development
535(44)
Per Holm
Morten Allesø
Mette C. Bryder
Rene Holm
21 ICH Q9 Quality Risk Management
579(32)
David Elder
Andrew Teasdale
22 ICH Q10 Quality Systems: ICH Q10 Implementation at Genentech/Roche
611(28)
Larry Wigman
Danny Ooi
23 ICH Q11: Development and Manufacture of Drug Substance
639(28)
Ronald Ogilvie
24 ICH M7: Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk
667(34)
Andrew Teasdale
Index 701
Andrew Teasdale, PhD, is a principal scientist in pharmaceutical development with AstraZeneca. He has over 20 years' experience within the industry and has held a number of leadership roles both internally and externally at a cross industry level encompassing key ICH topic areas.

David Elder, PhD, is an independent CMC consultant. He has 40 years' experience within the pharmaceutical industry. He was formerly a director within GlaxoSmithKline's platform technology and science function. He is an expert member for the British Pharmacopoeia and has extensive CMC experience encompassing many of the key ICH topics.

Raymond W. Nims, PhD, is a Senior Consultant at RMC Pharmaceutical Solutions, with experience in a variety of GMP quality assurance and quality control topics from a biologics point of reference. He has served on ad hoc panels supporting a number of USP chapters and ANSI Standards.